Platts Seeks Nominations for 2009 Global Energy Awards
NEW YORK, June 1 /PRNewswire-AsiaNet/ – Platts, a leading energy information provider and a division of The McGraw-Hill Companies (NYSE: MHP), is currently seeking nominations for the 11th annual Platts Global Energy Awards, which recognize excellence of companies and individuals in the global energy industry. Eighteen performance categories will be recognized. All nominations must be received... [Read More...]
Phase III Study Data With Vandetanib (Zactima(TM)) in Patients…
ORLANDO, FL, May 31 /PRNewswire-AsiaNet/– Data from the Phase III ZODIAC(1) study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, demonstrating that the addition of vandetanib to docetaxel resulted in... [Read More...]
Maintenance Treatment With Avastin and Tarceva in Combination …
BASEL, May 31 /PRNewswire-AsiaNet/ – – For ex-US Media Only – Phase III ATLAS Study Achieves a New Milestone in Treating Advanced Lung Cancer Roche announced today that the Phase III ATLAS study showed patients with advanced non-small cell lung cancer (NSCLC) who received Avastin(R) (bevacizumab) and Tarceva(R) (erlotinib) as combined first-line maintenance treatment had... [Read More...]
Induction Chemotherapy Followed by ChemoRadiotherapy Increased…
MADRID, May 30 /PRNewswire-AsiaNet/ – – Phase 3 study has demonstrated that Induction Chemotherapy prior to ChemoRadiotherapy significantly increased time-to-treatment failure in comparison to standard ChemoRadiotherapy alone - The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC) delivered prior to standard... [Read More...]
Westway Group, Inc. Declares $1 Special Dividend
NEW ORLEANS, May 30 /PRNewswire-AsiaNet/ – The Board of Directors of Westway Group, Inc. (OTC Bulletin Board: SACQ) today declared a special dividend of $1.00 per share to Class A Common shareholders of record on June 8, 2009, payable on June 18, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090529/DA24496LOGO) Westway Group, Inc. formerly known as Shermen WSC Acquisition Corporation is... [Read More...]
Fannie Mae Releases April 2009 Monthly Summary
WASHINGTON, May 30 /PRNewswire-AsiaNet/ – Fannie Mae’s (NYSE: FNM) April 2009 Monthly Summary is now available at www.fanniemae.com/ir/monthly. The monthly summary report contains information about Fannie Mae’s monthly and year-to-date activities for our gross mortgage portfolio, mortgage-backed securities and other guarantees, interest rate risk measures, and serious delinquency... [Read More...]
El Salvador’s Fixed and Mobile Data Markets will Double by 201…
CAMBRIDGE, Mass., May 30 /PRNewswire-AsiaNet/ – El Salvador’s fixed and mobile data markets will double in size by 2014 as mobile data services, fixed broadband, and pay-TV drive growth, according to a new report from Pyramid Research (www.pyr.com), the telecom research arm of the Light Reading Communications Network (www.lightreading.com). Communications Markets in El Salvador... [Read More...]
Avastin Plus Commonly Used Chemotherapies Improves the Time Br…
BASEL, May 29 /PRNewswire-AsiaNet/ – – RIBBON-1 Study Confirms Benefit of Avastin in Treating HER2-Negative Breast Cancer – For Non-US, Non-UK and Non-Austrian Media Results from the phase III RIBBON-1 study presented today at ASCO showed that patients with advanced HER2-negative breast cancer who were treated with Avastin(R) (bevacizumab) plus the most commonly used chemotherapies... [Read More...]
Fannie Mae Redemption
WASHINGTON, May 29 /PRNewswire-AsiaNet/ – Fannie Mae (NYSE: FNM) will redeem the principal amounts indicated for the following securities issues on the redemption dates indicated below at a redemption price equal to 100 percent of the principal amount redeemed, plus accrued interest thereon to the date of redemption: Principal Security Interest Maturity Date CUSIP Redemption... [Read More...]
New Preliminary Data from Two Studies Show Clinical Activity o…
COLLEGEVILLE, Pa., May 29 /PRNewswire-AsiaNet/ – Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) breast cancer, and a separate study investigating neratinib safety and efficacy when given with paclitaxel... [Read More...]
